Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Moderate Buy” by Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average recommendation of “Moderate Buy” by the sixteen analysts that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $19.07.

A number of brokerages have recently issued reports on HIMS. Piper Sandler lifted their price target on Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. TD Cowen boosted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their price target for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15. Following the completion of the sale, the insider now directly owns 166,809 shares in the company, valued at approximately $3,384,554.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15. Following the completion of the sale, the insider now directly owns 166,809 shares in the company, valued at approximately $3,384,554.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Patrick Harrison Carroll sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $13.00, for a total value of $130,000.00. Following the sale, the insider now owns 173,880 shares of the company’s stock, valued at $2,260,440. The disclosure for this sale can be found here. In the last 90 days, insiders sold 983,988 shares of company stock valued at $18,635,842. 17.71% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Nisa Investment Advisors LLC increased its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $48,000. Certuity LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $109,000. Belpointe Asset Management LLC increased its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the last quarter. Finally, Custom Index Systems LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $132,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $23.26 on Friday. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The firm has a market capitalization of $5.00 billion, a P/E ratio of -2,326.00 and a beta of 1.08. The stock has a 50 day moving average price of $20.92 and a 200 day moving average price of $15.15.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the company earned ($0.05) EPS. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Hims & Hers Health will post 0.2 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.